An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
Latest Information Update: 22 Nov 2023
At a glance
- Drugs ADR-001 (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors Rohto Pharmaceutical
- 17 Nov 2023 Status changed from recruiting to completed.
- 25 Oct 2022 Planned End Date changed from 30 Sep 2022 to 31 May 2023.
- 25 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 31 May 2023.